c-Met / HGFR
Los inhibidores de c-Met/HGFR apuntan al Receptor del Factor de Crecimiento de Hepatocitos (c-Met), una tirosina quinasa involucrada en procesos celulares como el crecimiento, la motilidad y la morfogénesis. La señalización de c-Met está implicada en la progresión del cáncer, la metástasis y la resistencia a terapias. Inhibir c-Met puede interrumpir el crecimiento y la propagación del tumor, lo que hace que estos inhibidores sean valiosos en la investigación del cáncer. En CymitQuimica, ofrecemos inhibidores de c-Met/HGFR para apoyar su investigación en oncología, metástasis y terapias contra el cáncer dirigidas.
Se han encontrado 148 productos para "c-Met / HGFR".
Filtrar por
Porcentaje de pureza
0
100
|
0
|
50
|
90
|
95
|
100
- Precio más bajo
- Precio más alto
- Pureza más baja
- Pureza más alta
- Entrega estimada más rápida
PROTAC c-Met degrader-1
CAS:PROTACc-Met degrader-1 (Compound Met-DD4) is an orally effective PROTAC degrader targeting c-Met with a DC50 of 6.21 nM. It inhibits the proliferation of c-Met-addicted MKN-45 cells with an IC50 of 4.37 nM and causes cell cycle arrest in the G0/G1 phase. In a xenograft mouse model using MKN-45 cells, PROTACc-Met degrader-1 demonstrates antitumor activity.Fórmula:C45H41FN10O5Forma y color:SolidPeso molecular:820.87Fosgonimeton acetate
Fosgonimeton acetate is an agonist of hepatocyte growth factor (HGF).Fórmula:C29H49N4O10PPureza:98.01%Forma y color:SolidPeso molecular:644.69Norleual
CAS:Angiotensin IV analog, potent HGF/c-MET inhibitor (IC50=3 pM), halts MDCK cell growth and invasion, AT4 antagonist, impairs LTP, antiangiogenic.Fórmula:C41H58N8O7Pureza:98%Forma y color:SolidPeso molecular:774.95Narnatumab
CAS:Narnatumab (IMC-RON8) is a humanized antibody that targets the macrophage-stimulating receptor 1 (RON). Narnatumab blocks the binding of RON to its ligand, macrophage-stimulating protein (MSP), and inhibits receptor activation, thereby suppressing tumor cell proliferation and migration. It is being investigated for the treatment of advanced malignant solid tumors.Pureza:>95%Forma y color:LiquidPeso molecular:145.8 kDa (Predicted)c-Met-IN-23
c-Met-IN-23 (Compound 12g) functions as a c-Met inhibitor with an IC50 of 0.052 μM against c-Met. It also inhibits the MDR1 and MRP1/2 pumps in cancerous HepG2 and BxPC3 cells. As such, c-Met-IN-23 serves as an anticancer agent.Fórmula:C16H13N7OPeso molecular:319.11816c-Met-IN-18
C-Met-IN-18, an ATP-competitive type-III inhibitor, targets both wild-type (WT) and D1228V mutant c-MET with IC50 values of 0.013 µM and 0.20 µM, respectively.Fórmula:C21H15FN4O2Pureza:98%Forma y color:SolidPeso molecular:374.37PROTAC c-Met degrader-3
PROTACc-Met degrader-3 (Compound 22b) is a c-Met PROTAC degrader. It facilitates the ubiquitination and degradation of c-Met, with a DC50 of 0.59 nM in EBC-1 cells. PROTACc-Met degrader-3 is applicable in lung cancer research.Fórmula:C51H54N10O7Forma y color:SolidPeso molecular:919.037LMTK3-IN-1
CAS:Lmtk3-in-1 is a potent ATP-competitive lemur tyrosine kinase 3 (LMTK3) (Kd=2.5 μM) inhibitor that degrades LMTK3 through the ubiquitin proteasome pathway.Fórmula:C18H11F3N4OPureza:99.58%Forma y color:Yellow SolidPeso molecular:356.3PROTAC c-Met degrader-2
CAS:PROTACc-Met degrader-2 (PROTAC2) is a c-Met degrader developed using PROTAC technology, with a DC50 value of 50 nM.Fórmula:C51H50F2N6O13Forma y color:SolidPeso molecular:992.97VEGFR-2/c-Met/EGFR-IN-2
VEGFR-2/c-Met/EGFR-IN-2 is an inhibitor targeting VEGFR-2, c-Met, and EGFR, with IC50 values of 0.32 μM, 0.021 μM, and 9.3 μM, respectively. Known as c-Met-IN-27, this compound inhibits the proliferation of cancer cells and demonstrates anti-angiogenic activity in vivo by suppressing neovascularization in the chick embryo chorioallantoic membrane (CAM) assay. It is applicable in research related to breast and lung cancers.Norleual TFA
Norleual TFA, Ang IV analog, inhibits HGF/c-Met (IC50: 3 pM), blocks AT4, and has strong antiangiogenic effects.Fórmula:C43H59F3N8O9Forma y color:SolidPeso molecular:888.97SYN1143
CAS:SYN1143 (AMG-1) strongly inhibits RON & c-Met with IC50s: 9 & 4 nmol/L.Fórmula:C31H29FN4O5Pureza:99.69%Forma y color:SolidPeso molecular:556.5842Anti-Human HGF Antibody (7V7)
Anti-HGF Antibody (7V7) is a mouse (varialbe region) / human (kappa / IgG1 constant) chimeric monoclonal antibody targeting Human HGF.PF-04217903 methanesulfonate
CAS:PF-04217903 methanesulfonate is a potent ATP-competitive inhibitor of c-Met kinase (Ki of 4.8 nM for human c-Met).Fórmula:C20H20N8O4SPureza:98%Forma y color:SolidPeso molecular:468.49Anti-Human MSPR/RON/CD136 Antibody (H5B14)
Anti-MSPR/RON/CD136 Antibody (H5B14) is a functional neutralizing antibody against RON, inhibiting tumor cell invasiveness and significantly delaying colorectal cancer progression by downregulating the MSP/RON signaling axis.Anti-Human MSPR/RON/CD136 Antibody
Anti-MSPR/RON/CD136 Antibody is a mAb targeting CD136 that exerts anti-tumor effects by inhibiting RON receptor phosphorylation and downstream PI3K and MAPK pathways.Anti-Human HGFR/c-Met Antibody 2
Anti-c-Met/HGFR Antibody is a humanized IgG1 monoclonal antibody that targets c-Met.Foretinib
CAS:Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.Fórmula:C34H34F2N4O6Pureza:98.07% - 99.68%Forma y color:SolidPeso molecular:632.6538Capmatinib 2HCl.H2O
CAS:Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.Fórmula:C23H21Cl2FN6O2Pureza:99.77%Forma y color:SolidPeso molecular:503.356Altiratinib
CAS:Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Forma y color:SolidPeso molecular:510.4645
